AbbVie
Price data unavailable
Track ABBV in your trading journalAbout AbbVie
When researching AbbVie, analysts typically begin with its Health Care sector positioning and Biotechnology industry dynamics. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
The company reports trailing twelve-month revenue of $15.00B and net income of $695.00M. Key metrics include a return on equity of -10.4%.
FINOTAUR provides free research summaries, news aggregation, and fundamentals for ABBV to support both active traders and long-term investors.
Fundamentals
| Revenue (TTM) | $15.00B |
| Net Income (TTM) | $695.00M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -10.44% |
| Debt-to-Equity | — |
| Dividend per Share | — |
Recent News
Want real-time analysis on ABBV?
Track it free in your trading journal. Log trades, tag setups, and review your edge.